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AbstrACt
Objectives To assess the risk of mortality in primary 
care patients, multimorbid (≥2 chronic conditions) or not, 
prescribed hypnotics/anxiolytics.
Design A longitudinal cohort study
setting Primary healthcare in the Reykjavik area.
Participants 114 084 individuals (aged 10–79 years, 
average 38.5, SD 18.4) contacting general practitioners 
during 2009–2012 (mortality follow- up to 31 December 
2016). Of those, the reference group comprised 58 560 
persons who were neither multimorbid nor had redeemed 
prescriptions for hypnotics/anxiolytics. Participants (16 
108) redeeming prescriptions for hypnotics/anxiolytics on 
a regular basis for 3 consecutive years were considered 
as consistent, long- term users. They were subdivided 
into low- dose (1–300 defined daily doses (DDD)/3 years), 
medium- dose (301–1095 DDDs/3 years) and high- dose 
users (>1095 DDDs/3 years). All six groups taking these 
drugs were compared with the reference group.
Main outcome measures All- cause mortality.
results HRs were calculated with the no multimorbidity—
no drug group as a reference, using Cox proportional hazards 
regression model adjusting for age, sex and the number 
of chronic conditions (n=111 767), patients with cancer 
excluded. During follow- up, 516 358 person- years in total, 
1926 persons died. Mean follow- up was 1685 days (4.6 
years), range 1–1826 days (5.0 years). For all multimorbid 
patients who took no drugs the HR was 1.14 (95% CI 1.00 
to 1.30) compared with those without multimorbidity. HRs in 
the non- multimorbid participants varied from 1.49 to 3.35 
(95% CI ranging from 1.03 to 4.11) with increasing doses of 
hypnotics/anxiolytics, and correspondingly from 1.55 to 3.52 
(1.18 to 4.29) in multimorbid patients.
Conclusions Mortality increased in a dose- dependent manner 
among both multimorbid and non- multimorbid patients taking 
hypnotics/anxiolytics. This increase was clearly associated with 
prescribing of these drugs. Their use should be limited to the 
recommended period of 2–4 up to 6 weeks; long- term use 
may incur increased risk and should be re- examined.
IntrODuCtIOn
In the last decades, various studies have 
expressed concerns about possible links 
between the use of hypnotic/anxiolytic 
benzodiazepine drugs and increased 
mortality.1–4 These studies have, however, 
shown inconsistent results. This can partly 
be explained by differences in methodology 
and design. Other studies have not lent 
support to a strong association of hypnotic 
use with increased mortality.5–7 A prospec-
tive study found that the risk of mortality was 
not significantly associated with hypnotic use 
regardless of type and duration.8 A retrospec-
tive cohort study correcting for a range of 
potential confounders found an association 
with significantly increased risk of mortality.9
Pharmacological properties of hypnotics 
could have an influence on mortality. Benzo-
diazepines and related drugs have respi-
ratory suppressant effects which can be 
 strengths and limitations of this study
 ► Our study is the first population- based longitudinal 
cohort study to compare dose- dependent mortality 
associated with long- term (3- year consistent) pre-
scribing of hypnotics/anxiolytics in multimorbid ver-
sus non- multimorbid patients.
 ► We retrieved International Classification of Diseases 
and Related Health Problems 10th Version diag-
noses from a large data set of medical records of 
healthcare centres serving two- thirds of the entire 
population and linked with data on redeemed pre-
scriptions from the national drug prescription data-
base and mortality data from the national mortality 
registration database.
 ► Information on some confounding factors was lack-
ing and confounding by indication cannot be avoid-
ed, so even after adjusting for chronic conditions 
some residual confounding may still be present.
 ► The definition of multimorbidity is not universally 
standardised and may be heterogeneous to a cer-
tain extent.
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increased in combination with other respiratory depres-
sant drugs or alcohol.10 Recently, the focus has been 
on opioids in the USA where a considerable number 
of opioid users were coadministered benzodiazepines 
leading to increased mortality.11 An Icelandic study 
found increased mortality in patients undergoing non- 
cardiac surgery who received a preoperative prescription 
for both opioids and benzodiazepines. This was not the 
case when opioids or benzodiazepines were prescribed 
separately.12 The use of psychotropic drugs leads to risk 
of falls and fractures,13 14 and hip fractures markedly 
increase mortality in the elderly.15 An increased suicide 
risk has been reported in persons taking these drugs 
leading to increased mortality.3 16 Other untoward effects 
could also increase mortality such as an increased risk 
of road traffic accidents,17 dementia18 and Alzheimer’s 
disease.19 20 Other studies do not support a causal asso-
ciation between benzodiazepine use and dementia.21 An 
association was found between exposure to benzodiaze-
pines and increased mortality from community- acquired 
pneumonia.22 To summarise, all this could contribute to 
increased mortality.
We are only aware of one prior general practice study 
clearly showing a dose- dependent relationship between 
mortality and use of these drugs.9 We consider that 
defining long- term use as 3 consecutive years of consis-
tent use with up to 5 years of follow- up (3 years expo-
sure+5 years follow- up=8 years) in both multimorbid 
and non- multimorbid patients will further evidence the 
relationship between use of these drugs and mortality. 
Multimorbidity is known to be associated with increased 
mortality.23 24
The aim of this study is to analyse a possible difference 
in risk of mortality (hazard) in persons either multi-
morbid or not, prescribed hypnotics/anxiolytics or not, 
by comparing the different groups to patients who neither 
were multimorbid nor had been prescribed hypnotics/
anxiolytics. Furthermore, to find whether there could be 
a dose- dependent risk of mortality in long- term users of 
hypnotics/anxiolytics.
MAterIAls AnD MethODs
 Design and setting
The Primary Healthcare of the Capital Area (PHCA) 
includes most of the primary healthcare centres (PHC) 
in the Reykjavik area with a population of just over 200 
000. The PHCs are staffed by general practitioners (GP), 
midwives, nurses and other personnel. Information 
on age and sex of all patients who had contacted the 
PHCA during a 4- year period from 1 January 2009 to 31 
December 2012 was retrieved from the PHCA medical 
records database, as well as the diagnosis (International 
Classification of Diseases and Related Health Problems 
10th Version; ICD-10) for chronic conditions as described 
in a previous paper25 (see online supplementary table 
1). The data in the PHCA medical records database are 
stored under a unique personal identifier (ID) allocated 
to every inhabitant.
 exposure
The extracted data were linked through the patients’ IDs 
with data on redeemed hypnotic/anxiolytic prescriptions 
in the Icelandic Medicine Register (IMR). All redeemed 
prescriptions for hypnotics/anxiolytics with the Anatom-
ical Therapeutic Chemical (ATC) codes N05BA, N05CD 
and N05CF were retrieved and collected in the study 
database. The use of hypnotics/anxiolytics was classi-
fied into two categories: Z- drugs and benzodiazepines. 
Individual drugs prescribed are listed in online supple-
mentary table 2. In this study we employ the term inter-
mittent user for those who were prescribed hypnotics/
anxiolytics occasionally during the 4- year period for less 
than 3 consecutive years, whereas long- term users are 
those who used hypnotics/anxiolytics consistently during 
at least 3 consecutive years. Low- dose users were defined 
as those who used 1–300 defined daily doses (DDD)/3 
years, medium- dose users as those who used 301–1095 
DDDs/3 years and high- dose users as those who used 
>1095 DDDs/3 years. The upper limit for the low dose is 
three prescriptions per year according to clinical guide-
lines (4–6 weeks) over 3 consecutive years. High- dose use 
is one dose or more per day, also over 3 consecutive years 
(365×3=1095).
 Covariates
In this paper we apply the commonly used definition of 
multimorbidity as the presence of two or more chronic 
medical conditions in the same person, and we use previ-
ously described conditions as the frame of reference.25 
In the Cox proportional regression analysis, adjustment 
was made for the number of chronic conditions. The 
groups were as follows: no multimorbidity group (zero or 
one chronic condition) and multimorbidity group (2–3, 
4–5, 6–7 or 8–15 chronic conditions). The list of chronic 
conditions used in this study coded by the ICD-10 is to 
be found in online supplementary table 1. Insomnia is 
not among the listed conditions as we presumed it was 
an inclusive part of the decision to prescribe a hypnotic. 
Distribution of age and sex in the cohort is to be found in 
table 1 showing baseline characteristics.
 Outcome
Information on mortality in the cohort was extracted by 
linking the IDs with relevant data in the National Cause 
of Death Registry. When all relevant data for the study 
database had been linked through the subjects’ IDs it was 
encrypted so the personal identity of the patients would 
not be revealed during the processing of the data set 
which was collected in a study database.
 subject groups and statistical analysis
The mortality of primary care patients, multimorbid or not, 
who were consistent users of hypnotics/anxiolytics during 
a 3- year period in the time interval from 1 January 2009 
to 31 December 2012 was determined and compared with 
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Table 1 Baseline characteristics of participants in the longitudinal cohort study in primary care in Iceland
Group and drug dose
No multimorbidity Multimorbidity






Individuals (n) n=947 n=1454 n=912 n=3240 n=5448 n=4107
Age (years) 30.9 51.3 57.6 58.1 42.2 53.9 58.9 59.6
SD (years) 15.3 15.2 14.1 14.1 17.4 14.0 13.0 12.8
Men (%) 51.7 39.6 39.9 44.1 47.3 31.2 32.4 32.9
Women (%) 48.3 60.4 60.1 55.9 52.8 68.8 67.6 67.1
2–3 chronic conditions (%) na na na na 69.0 39.8 31.1 23.6
4–5 chronic conditions (%) na na na na 23.5 36.6 35.2 31.8
6–7 chronic conditions (%) na na na na 6.0 16.6 22.3 25.8
8–15 chronic conditions (%) na na na na 1.6 7.0 11.4 18.8
Z- drugs (Z) only (%) na 40.9 44.4 24.9 na 43.6 49.5 26.9
Benzodiazepines (BZD) only 
(%)
na 27.9 15.3 14.0 na 26.7 12.8 10.0
Z and BZD (%) na 31.3 40.4 61.1 na 29.7 37.7 63.1
Z- drugs and/or benzodiazepines (DDDs/3 years)
  Mean na 166.2 639.2 2090.4 na 168.4 657.6 2136.9
  SD na 75.7 224.4 1278.5 na 76 228.9 1515.6
  5th percentile na 42.5 330 1120 na 45 330 1110
  25th percentile na 107.5 450 1290 na 110 455.9 1247
  50th percentile na 162.5 600 1620 na 167.5 630 1597.5
  75th percentile na 230 810 2361 na 137.5 840 2353.5
  95th percentile na 290 1050 4765 na 294.4 1050 5020
Benzodiazepines (DDDs/3 years)
  Mean na 59.4 180.1 883.6 na 55.2 150.5 808
  SD na 79.2 266.6 1218.9 na 77 247.9 1274.9
  5th percentile na 0 0 0 na 0 0 0
  25th percentile na 0 0 5 na 0 0 0
  50th percentile na 20 20 381.3 na 15 5 285
  75th percentile na 100 325 1331 na 90 222.5 1175
  95th percentile na 240 750 3239 na 235 700 3100
Z- drugs (DDDs/3 years)
  Mean na 106.8 459.8 1206.8 na 113.3 507.1 1328.9
  SD na 94.3 313.8 953.8 na 96.2 318.5 1096.7
  5th percentile na 0 0 0 na 0 0 0
  25th percentile na 0 220 610 na 0 320 900
  50th percentile na 100 480 1160 na 120 510 1184
  75th percentile na 180 690 1560 na 190 750 1590
  95th percentile na 270 990 2820 na 270 1020 3090
Multimorbidity: the presence of two or more chronic medical conditions in the same person.
*Defined daily doses of Z- drugs and/or benzodiazepines used during a 3- year recruitment period (from 2009 to 2012).
na, not applicable.
non- multimorbid subjects not using hypnotics/anxiolytics 
(figure 1). A flow chart (figure 2) shows who were excluded 
in our study. We ended up with 114 084 participants who 
could be divided into four groups: (A) 58 560 persons 
who were neither multimorbid nor had been prescribed 
hypnotics/anxiolytics, (B) 12 795 multimorbid patients 
who had been prescribed hypnotics/anxiolytics, (C) 39 
416 multimorbid patients who had not been prescribed 
hypnotics/anxiolytics and, finally, (D) 3313 persons who 
were not multimorbid but had been prescribed hypnotics/
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Figure 1 Participant inclusion/exclusion to the study. Schematic presentation of participant inclusion/exclusion to the study, 
their exposure to anxiolytics (ATC classification N05B) and/or hypnotics/sedatives (ATC classification N05C) during a 3- year 
recruitment period/exposure window. Participants contacted the Primary Healthcare of the Capital Area in Reykjavik and its 
adjacent towns during 2009, and the follow- up started 3 years after first prescription or first visit. Persons who redeemed 
prescriptions for the above- mentioned drugs for 3 consecutive years were included and considered consistent (long- term 
users). ATC, Anatomical Therapeutic Chemical.
anxiolytics. Thus, 16 108 patients had redeemed prescrip-
tions for hypnotics/anxiolytics in the relevant ATC classes 
on a regular basis for 3 consecutive years and were consid-
ered as consistent or long- term users. They were divided 
into multimorbid and non- multimorbid subjects. Both 
these groups were subdivided into low- dose users (1–300 
DDDs/3 years), medium- dose users (301–1095 DDDs/3 
years) and high- dose users (>1095 DDDs/3 years), all 
six groups compared with those who neither were multi-
morbid nor took hypnotics/anxiolytics and were set as a 
reference. It can be argued whether patients who use 1–300 
DDDs/3 years can be defined as consistent users. However, 
we include them in order to reveal if low- dose use during 
a long time is associated with mortality. For all the patients 
who did not die during follow- up, the follow- up ended 31 
December 2016.
We used Cox proportional regression analysis to deter-
mine the relative risk, that is, HR for all- cause mortality 
during the follow- up while adjusting for age, sex and the 
number of chronic conditions (tables 2 and 3). The non- 
multimorbid participants not using hypnotics/anxiolytics 
during the years 2009–2012 were used as a reference. 
For the Nelson- Aalen cumulative hazard we restricted 
the analysis to participants aged 40–79 years in order to 
even the average age in the groups compared. Signifi-
cance testing was two sided and based on a 5% proba-
bility level. We tested the Cox models for violations of 
the proportional hazard assumption.26 27 The assumption 
was not violated in the main analyses. Three sensitivity 
analyses were performed. In the first sensitivity analysis 
using subjects aged 10–69 years the proportional hazard 
assumption was violated. By left truncating the follow- up 
by 120 days the assumption was no longer violated. This 
resulted in somewhat lower HRs (by 4%–20%, table 3, 
model 3). The second sensitivity analysis was performed 
including participants aged 10–59 years. No left trun-
cation was needed in the regression analysis. The third 
sensitivity analysis included participants aged 10–79 years, 
but the maximum cumulative dose of hypnotics and/
or anxiolytics was 42 DDDs/year, thus approximating 
the maximum duration (6 weeks) of a clinically recom-
mended drug treatment with hypnotic- sedatives. The 
software package used was Stata V.13 (StataCorp, College 
Station, TX, USA).
ethics approval
The National Bioethics Committee and the Data Protec-
tion Authority in Iceland approved the study (VSN 
16-151).
Public and Patient Involvement
No patients were involved in the research process at any 
stage. Patient consent not required.
results
At study entry the number of participants was 114 084; 
54 400 men and 59 684 women, with an average age of 
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Figure 2 Flow chart of participants included in the longitudinal cohort study in primary care in Iceland.
38.5 years, SD 18.4, and an age range of 10–79 years. 
Table 1 shows the baseline characteristics of the study 
participants. The average age of those who were neither 
multimorbid nor had used hypnotics/anxiolytics was 30.9 
years. The multimorbid patients were 11 years older on 
the average. Individuals, either multimorbid or not, using 
hypnotics/anxiolytics were approximately 20–30 years 
older than those neither multimorbid nor using these 
drugs (table 1). Among multimorbid users of hypnotics/
anxiolytics the prevalence of those with six to seven or 
eight or more chronic conditions went hand in hand with 
increasing use (low, medium, high dose) of hypnotics/
anxiolytics (table 1). Compared with people without 
multimorbidity and no use of hypnotics/anxiolytics, 
those without multimorbidity but with a consistent 3- year 
hypnotic/anxiolytic use were at increased risk of mortality 
from all causes across all three dose categories, HRs 
varied from 1.49 to 3.35 depending on dose (results and 
95% CIs in table 2, model 3). Likewise, compared with 
people without multimorbidity and no use of hypnotics/
anxiolytics, those with multimorbidity and with consistent 
3- year hypnotic/anxiolytic use were at increased risk of 
mortality from all causes across the three dose categories, 
HRs varying from 1.55 to 3.52 (table 2, model 3). When 
excluding use of hypnotics/anxiolytics, multimorbid 
subjects compared with those without multimorbidity 
were at a borderline significantly increased risk of all- 
cause mortality, the HR was 1.14 (95% CI 1.00 to 1.30, 
p=0.049) (table 2, model 1). A similar pattern emerged 
when plotting the Nelson- Aalen cumulative hazard for 
the groups mentioned above, participants were at higher 
risk of mortality when using high doses of hypnotics/
anxiolytics (figure 3). Using the same reference group 
as above, a sensitivity analysis among participants 10–69 
years old (n=107 121) revealed similar findings. Those 
who were not multimorbid but with a consistent 3- year 
use of hypnotics/anxiolytics were at increased risk of 
mortality from all causes across all three dose categories 
the HRs varying from 1.97 to 5.59 (results and 95% CIs 
in table 3, model 3). Similarly, multimorbid participants 
using low, medium or high doses of hypnotics/anxiolytics 
were at increased risk of mortality, the HRs being from 
2.37 to 5.93 (table 3, model 3).
In the second sensitivity analysis participants aged 
10–59 years were included. The endpoints were too few, 
both in the low- dose and the medium- dose groups, for 
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calculating HR. When omitting patients with cancer, the 
adjusted HR was 8.96 (95% CI 5.72 to 14.02, n=337, 13 
deaths) for those without multimorbidity and high dose 
of hypnotics/anxiolytics. Similarly, for those with multi-
morbidity and high dose of hypnotics/anxiolytics, the 
adjusted HR was 11.92 (95% CI 7.33 to 19.37, n=1905, 102 
deaths). The third sensitivity analysis where the annual 
maximum cumulative dose of hypnotics/anxiolytics was 
42 DDDs (126 DDDs/3 years), the average annual dose 
of hypnotics/anxiolytics for the first year was 22.8 DDDs, 
SD=10.5; 20.0 DDDs, SD=10.8 for the second year and 20.4 
DDDs, SD=10.9 for the third year. Among those without 
multimorbidity (n=115) there was only one death during 
the follow- up and therefore, an HR is not reported here. 
For those with multimorbidity HR was 1.13 (95% CI 0.53 
to 2.40, n=693, 12 deaths).
Participants with two or three chronic conditions were 
not at increased risk of mortality compared with those 
with zero or one chronic condition. The risk of mortality 
when chronic conditions were four or five rose to HR 1.09 
(95% CI 0.97 to 1.29) for those aged 10–79 years, and 
HR 1.21 (95% CI 1.03 to 1.43) for ages 10–69 years. The 
greatest risk of mortality was linked to having six to seven, 
and eight or more chronic conditions (online supple-
mentary table 3 and 4).
DIsCussIOn
 Principal findings
Consistent long- term users of benzodiazepines/Z- drugs, 
either multimorbid or not, were subdivided into low- dose 
users (1–300 DDDs/3 years), medium- dose users (301–
1095 DDDs/3 years) and high- dose users (>1095 DDDs/3 
years). The mortality among both the multimorbid and 
non- multimorbid patients prescribed these drugs over a 
period of 3 years increased in a dose- dependent manner. 
This increase was clearly associated with the prescribing 
of these drugs. In this paper we often apply the term use 
when strictly speaking it involves prescribing.
 strengths
This is a comprehensive study covering approximately 
two- thirds of the total population where all contacts with 
the vast majority of the healthcare centres in the area are 
registered in the medical records database. The distri-
bution according to age and sex is the same as for the 
population at large so the cohort is truly representative. 
By linking the IDs to the data on redeemed prescriptions 
in the IMR during the study period we were able to cover 
all the prescriptions issued by the GPs.
 limitations
The definition of multimorbidity is not universally stan-
dardised. Although there seems to be a broad consensus 
on a considerable number of different chronic diseases 
covered by the definition of two or more chronic diseases 
in one person, it does not cover all diseases that have been 
included by various authors, thus making the definition 
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Figure 3 Dose- dependent mortality in relation to a 3- year consistent use of hypnotics/anxiolytics. Graph on the left: mortality 
(Nelson- Aalen cumulative hazard) among individuals aged 40–79 years, with no multimorbidity in relation to a 3- year consistent 
use of hypnotics/anxiolytics. Drug dose classified as: ‘low’ 1–300 defined daily doses (DDD) over 3 years before follow- up 
day 0; ‘medium’ 301–1095 DDDs over 3 years; ‘high’ >1095 DDDs/3 years, n=16 978. Patients with cancer diagnosis were 
excluded, n=81. Graph on the right: mortality (Nelson- Aalen cumulative hazard) among multimorbid patients aged 40–79 years, 
in relation to 3- year consistent use of hypnotics/anxiolytics in different doses. Drug dose classified as: ‘low’ 1–300 DDDs over 
3 years before follow- up day 0; ‘medium’ 301–1095 DDDs/3 years; ‘high’ >1095 DDDs/3 years, n=32 420. Patients with cancer 
diagnosis were excluded, n=2089 (Same classification of multimorbidity and drug use is also used in tables 1 and 2).
heterogeneous to a certain extent. The nature of the 
diseases, the disease combinations and the different number 
of diseases per patient above the minimum of 2 add to its 
variability.28 Furthermore, the burden of disease can vary 
depending on the severity and nature of the disease combi-
nations, age of the patient, and so on, as well as its impact 
on the outcome, including mortality. A previous study 
revealed that in multimorbid, incident patients receiving 
hypnotic/anxiolytic prescriptions, a combination of mental 
disorders and pain- related diagnoses dominated the clin-
ical profile.25 Potential confounders that we lack informa-
tion on include use of other respiratory suppressant drugs, 
alcohol consumption, smoking, social status, education and 
income. Moreover, confounding by indication is inevitable. 
If we consider confounders not registered in the current 
study, residual confounding and potential non- adherence 
to treatment, then we may expect the HRs to attenuate to 
some degree.
 Multimorbidity
In the aforementioned study, we explored the relationship 
between multimorbidity and the use of hypnotic and anxio-
lytic drugs. Multimorbid patients were far more likely to use 
hypnotics/anxiolytics compared with those without multi-
morbidity, OR=14.9 (95% CI 14.4 to 15.4).25 Looking at the 
mortality of all the multimorbid patients who did not use 
hypnotics/anxiolytics, we found it to be around 14% higher 
(95% CI 0% to 30%) than in patients neither multimorbid 
nor using hypnotic/anxiolytic drugs. This is comparable to 
increased mortality of multimorbid individuals reported 
in other studies.23 24 Grouping participants by the number 
of chronic conditions, setting no multimorbidity (zero or 
one chronic condition) as a reference, revealed an increase 
in the risk of mortality among individuals with four to five 
conditions or more. The risk increased with increasing 
number of chronic conditions.
 Drug dose and morbidity
We defined long- term use of hypnotics/anxiolytics rela-
tively evenly spread over time as consistent use during a 
3- year period. We divided the participants into low- dose, 
medium- dose and high- dose users. It may be argued 
whether the low- dose users can be called consistent users, as 
the intervals between prescriptions may at times have been 
somewhat irregular, but they redeemed the drugs every 
now and then during the 3 consecutive years being studied. 
Moreover, 75% of low- dose users took between 100 and 300 
DDDs of the drugs during the 3- year recruitment period. 
Compared with mortality in patients neither multimorbid 
nor using hypnotics/anxiolytics, the cumulative hazard 
curves rise steadily with increasing dose for both multi-
morbid and non- multimorbid patients using hypnotics/
anxiolytics. To account for considerable differences in the 
average age between those who used hypnotics/anxiolytics 
and those who did not, the hazard curves were restricted 
to persons from 40 to 79 years of age. These results show 
that the contribution of multimorbidity to the mortality 
is fairly constant following the 3- year recruitment/expo-
sure period under investigation, the increase in mortality 
first and foremost associated with the dose of hypnotics/
anxiolytics which might point to these drugs as a culprit in 
this increase in mortality. In the sensitivity analysis where 
persons aged 70–79 years were omitted, the risk of all- cause 
mortality in relation to drug dose increased consistently 
across all groups, from an adjusted HR 3.35 (persons 10–79 
years of age) to HR 5.59 (persons aged 10–69 years) in 
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non- multimorbid individuals, and from HR 3.52 to HR 5.93 
in those who were multimorbid. This reflects a lower base-
line risk in younger individuals and may have to be consid-
ered when prescribing these drugs.
In the second sensitivity analysis, when excluding the 
sexagenarians (60–69) the endpoints were too few in 
number, both in the low- dose and the medium- dose 
groups, for calculating HR. When omitting patients with 
cancer, the adjusted HR was 8.96 (95% CI 5.72 to 14.02) for 
those with no multimorbidity and high dose of hypnotics/
anxiolytics, and similarly for those with multimorbidity and 
high dose of hypnotics/anxiolytics the adjusted HR was 
11.92 (95% CI 7.33 to 19.37). The risk observed in indi-
viduals aged 10–59 years using high doses of hypnotics/
anxiolytics is a further indication of higher risk of early 
mortality among younger persons associated with high- dose 
use of these drugs compared with corresponding groups 
of older persons. The third sensitivity analysis was done 
in order to resemble a cumulative dose for 6 weeks’ treat-
ment with hypnotics and/or anxiolytics. We cannot draw 
any conclusions regarding persons without multimorbidity, 
since only one endpoint occurred during the follow- up, but 
among those with multimorbidity the HR was 1.13 (95% CI 
0.53 to 2.40) which does not indicate an increased risk of 
mortality for using up to 42 DDDs/year of hypnotics and/
or anxiolytics. A Danish study involving men born in 1953 
living in Denmark 1 January 199629 did not find an associ-
ation between mortality and low- dose use of hypnotics (an 
average of ≤30 DDDs/year, HR=1.22, 95% CI 0.97 to 1.54). 
An association was found in high- dose users (ie, >30 DDDs/
year, HR=1.43, 95% CI 1.11 to 1.85). This is in accordance 
with our results. In the above- mentioned sensitivity anal-
ysis multimorbid patients using 42 DDDs/year were not at 
increased risk of mortality.
In a retrospective, matched cohort study on the effect of 
anxiolytic and hypnotic prescriptions on mortality hazards,9 
the risk followed a dose–response pattern both for benzo-
diazepines and Z- drugs and did not seem to be entirely due 
to confounding by physical or psychiatric comorbidity or 
prescribing of other drugs. In that study an exposure of 
1–30 DDDs of hypnotic/anxiolytic drugs was associated 
with HR 2.55 (95% CI 2.42 to 2.69), and an exposure of 
≥91 DDDs was associated with HR 4.51 (95% CI 4.22 to 
4.82). When the analysis was confined to subjects with a 
12- month follow- up or more, the corresponding HRs were 
attenuated, 1.45 (95% CI 1.35 to 1.56) and 2.63 (95% CI 
2.34 to 2.95), thus indicating a dose–response, which is in 
accordance with our findings.
 Different interpretations of results
Other views have been presented, for example, in a study 
connecting disease burden and use of hypnotics, showing 
a 50% increase in the use of benzodiazepines 24 months 
before death. The authors concluded that the associa-
tion between use of these drugs and mortality is at least 
partially due to confounding.30 A Finnish study where the 
purchase of hypnotic drugs registered in a nationwide 
database was followed for up to 7.6 years, deaths in the 
cohort were matched with control cases. According to the 
authors’ interpretation the developmental trajectories of 
purchases were differently and plausibly associated with 
specific mortality risks. They concluded that the associa-
tion was created without specific biological mechanisms by 
symptomatic treatment of discomfort caused by terminal 
illness.31 In our study, we have eliminated persons closely 
approaching death by requiring a 3- year period of consis-
tent use, and subsequently, for the participants for whom 
follow- up for mortality was started, the average follow- up 
time was 4.6 years. In addition, to address the potential 
confounding effects of terminal illness, subjects with cancer 
diagnosis were excluded in risk estimates (table 2, model 3; 
table 3, model 3). These measures reduce the risk of reverse 
causation bias.
 Influence of pharmacological effects
The pharmacological properties of hypnotics could play 
a role in mortality in these patients as mentioned in 
the Introduction section. The respiratory suppressant 
effects of benzodiazepines and related drugs increase 
in combination with other respiratory depressant drugs 
or alcohol.10 In the Introduction section, we already 
mentioned coadministration of opioids and benzodiaze-
pines,11 12 and also use of psychotropic drugs leading to 
increased risk of falls and fractures and as a consequence 
increased mortality in the elderly,13–15 the possible associ-
ation with increased suicide risk,3 16 increased risk of road 
traffic accidents,17 dementia18 and Alzheimer’s disease.19 20 
Exposure to benzodiazepines has been found to be asso-
ciated with an increased risk of community- acquired 
pneumonia and consequently increased mortality.22 A 
Canadian population- based cohort study found that 
when adults aged 66 years and older with chronic obstruc-
tive pulmonary disease were examined within 30 days of 
incident benzodiazepine use, new benzodiazepine users 
were at significantly higher risk for outpatient respiratory 
exacerbation compared with non- users.32 Evidently, the 
above- mentioned points could all contribute to increased 
mortality, separately and/or jointly. Multimorbidity as 
such is associated with increased mortality.23 24
COnClusIOns
The increase in mortality with increasing doses of hypnotics/
anxiolytics in both the multimorbid patients and those 
without multimorbidity might possibly be a consequence 
of the use of these drugs as there is a dose- dependent 
increase in mortality in both categories of patients with 
a similar difference between the corresponding groups 
(multimorbid – non- multimorbid). Our findings support 
the general recommendations that the use of benzodiaze-
pines and Z- drugs should be limited to a period of 2–4 up 
to 6 weeks, long- term use being associated with increased 
risk. When possible, non- pharmacological approaches 
should be sought to treat long- term sleeping problems, for 
example, cognitive–behavioural therapy and by teaching 
better sleeping habits.33–35
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